PE20070855A1 - Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas - Google Patents

Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas

Info

Publication number
PE20070855A1
PE20070855A1 PE2006001518A PE2006001518A PE20070855A1 PE 20070855 A1 PE20070855 A1 PE 20070855A1 PE 2006001518 A PE2006001518 A PE 2006001518A PE 2006001518 A PE2006001518 A PE 2006001518A PE 20070855 A1 PE20070855 A1 PE 20070855A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
substituents
halogen
amino
Prior art date
Application number
PE2006001518A
Other languages
English (en)
Inventor
Julie A Dixon
Steven Magnuson
Barton Phillips
Yamin Wang
Tindy Li
Kyle Parcella
Jason Newcom
Harold Kluender
Zhenqiu Hong
Brent Chandler
Zhongua Zhang
Kristen Allegue
Zheng Liu
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20070855A1 publication Critical patent/PE20070855A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLOTRIAZINA DE FORMULA (I) DONDE R1 ES FENILO O UN CARBOCICLO BICICLICO DE 9 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C4), CICLOALQUILO(C3-C6), HALOGENO, CN, ENTRE OTROS SUSTITUYENTES, HETEROCICLO AROMATICO DE 5 A 6 MIEMBROS QUE TIENE HASTA 3 HETEROATOMOS, HETEROCICLO BICICLICO DE 8 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C4), NO2, CN, ENTRE OTROS SUSTITUYENTES, ENTRE OTROS; R2 ES HALOGENO, ALQUILO(C1-C5) U O-ALQUILO(C1-C3); R3 ES ALQUILO(C1-C5) OPCIONALMENTE SUSTITUIDO CON HALOGENO, FENILO, CN, ENTRE OTROS SUSTITUYENTES, HETEROAROMATICO DE 5 A 6 MIEMBROS QUE TIENE HASTA 2 HETEROATOMOS SELECCIONADOS DE O, S O N, HALOGENO, CN, ENTRE OTROS; R4 ES ALQUILO(C1-C5) OPCIONALMENTE SUSTITUIDO CON CICLOALQUILO(C3-C5), HALOGENO, FENILO, ENTRE OTROS SUSTITUYENTES, HALOGENO, CN, UN COMPUESTO DE FORMULA (II) DONDE q ES DE 1 A 3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{4-[4-AMINO-6-(METOXIMETIL)-7-(MORFOLIN-4-ILMETIL)-PIRROLO[2,1-f][1,2,4]TRIAZIN-5-IL]FENIL}-N'-[2-FLUORO-5-(TRIFLUOROMETIL)FENIL]UREA, N-(4-{4-AMINO-6-(METOXIMETIL)-7-[(4-METILPIPERAZIN-1-IL)METIL]-PIRROLO[2,1-f][1,2,4]TRIAZIN-5-IL}FENIL)-N'-[2-FLUORO-5-(TRIFLUOROMETIL)FENIL]UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS TALES COMO PSORIASIS, CANCER DE MAMA, SARCOMA
PE2006001518A 2005-12-02 2006-11-29 Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas PE20070855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74215105P 2005-12-02 2005-12-02

Publications (1)

Publication Number Publication Date
PE20070855A1 true PE20070855A1 (es) 2007-10-14

Family

ID=38092821

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001518A PE20070855A1 (es) 2005-12-02 2006-11-29 Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas

Country Status (18)

Country Link
US (2) US8133995B2 (es)
EP (2) EP2465505A1 (es)
JP (1) JP5199882B2 (es)
KR (1) KR101404290B1 (es)
CN (2) CN101365454B (es)
AR (1) AR057991A1 (es)
AU (1) AU2006320480B2 (es)
BR (1) BRPI0619153B8 (es)
CA (1) CA2631775C (es)
DO (1) DOP2006000269A (es)
ES (1) ES2459016T3 (es)
HK (1) HK1129305A1 (es)
IL (1) IL191864A (es)
PE (1) PE20070855A1 (es)
TW (1) TWI388560B (es)
UY (1) UY29983A1 (es)
WO (1) WO2007064883A2 (es)
ZA (1) ZA200805694B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN101466710B (zh) * 2005-12-02 2013-05-29 拜尔健康护理有限责任公司 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
EP2203060A4 (en) * 2007-09-25 2010-12-22 Bayer Healthcare Llc PYRROLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER BY INHIBITING AURORA KINASE
BRPI0911410A2 (pt) 2008-04-23 2015-10-06 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
JP6196551B2 (ja) * 2010-04-12 2017-09-13 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジン塩を製造する方法及びその新規な多形
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2012280508A1 (en) 2011-07-01 2013-12-12 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
PE20141681A1 (es) 2011-07-19 2014-11-14 Merck Sharp And Dohme B V Inhibidores de btk
SG11201402196YA (en) * 2011-11-18 2014-10-30 Hoffmann La Roche Release reagent for vitamin d compounds
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2791143B1 (en) 2011-12-15 2016-02-24 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
EP2817311B1 (en) 2012-02-23 2016-04-06 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20140206681A1 (en) 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
WO2014113932A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
US10328080B2 (en) 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
WO2015095099A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
EP3209664B1 (en) * 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
EP3317281B1 (en) 2015-07-02 2020-04-22 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
CA2998189C (en) 2015-09-16 2021-08-03 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US20190135798A1 (en) 2015-11-02 2019-05-09 Basf Se Substituted Oxadiazoles for Combating Phytopathogenic Fungi
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CA3019145A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
US10478730B1 (en) 2016-08-25 2019-11-19 Electronic Arts Inc. Computer architecture for simulation of sporting events based on real-world data
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
CN106974892A (zh) * 2017-05-03 2017-07-25 亿腾药业（泰州）有限公司 一种含有4‑氨基‑吡咯并三嗪衍生物类激酶抑制剂的药物组合物及其制备方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
EA202091777A1 (ru) 2018-01-26 2020-10-14 Бристол-Маерс Сквибб Компани Аминопирролотриазины в качестве ингибиторов киназы
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN109232583A (zh) * 2018-11-29 2019-01-18 尚科生物医药（上海）有限公司 一种6-溴-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮的制备方法
EA202192133A1 (ru) * 2019-01-31 2022-02-09 Байер Акциенгезельшафт Моногидрат гидрохлорида рогаратиниба и его твердые состояния
CN109928976A (zh) * 2019-02-26 2019-06-25 泰州亿腾景昂药业有限公司 一种工业化生产eoc317的方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021154687A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN115298181A (zh) 2020-03-12 2022-11-04 吉利德科学公司 制备1’-氰基核苷的方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
PE20231983A1 (es) 2020-08-27 2023-12-12 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales
CN112830930B (zh) * 2020-12-18 2022-06-07 泰州亿腾景昂药业股份有限公司 Eoc317的晶型及其制备方法与应用
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN113831255B (zh) * 2021-11-25 2022-03-11 山东诚创蓝海医药科技有限公司 一种2-氨基丙二酰胺的制备方法
CN114456099A (zh) * 2022-02-21 2022-05-10 八叶草健康产业研究院(厦门)有限公司 一种4-氯吡咯-2-羧酸的制备方法
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN114685301A (zh) * 2022-03-31 2022-07-01 山东省药学科学院 一种2-氨基丙二酰胺的生产改良方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629301A (en) 1969-10-24 1971-12-21 Du Pont 3 3-difluoro-2-substituted steroids and their preparation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
NZ524842A (en) * 1998-01-28 2003-10-31 Bristol Myers Squibb Pharma Co Azolo triazines and pyrimidines
NZ516292A (en) * 1999-05-21 2004-01-30 Bristol Myers Squibb Co Pyrrolotriazine inhibitors of kinases
IL148718A0 (en) * 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
DE60037455T2 (de) * 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
JP2005508904A (ja) * 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
US6951859B2 (en) 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2004108672A1 (en) 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN101466710B (zh) * 2005-12-02 2013-05-29 拜尔健康护理有限责任公司 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP2203060A4 (en) 2007-09-25 2010-12-22 Bayer Healthcare Llc PYRROLOTRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER BY INHIBITING AURORA KINASE

Also Published As

Publication number Publication date
CN101365454B (zh) 2016-03-30
BRPI0619153A2 (pt) 2011-09-20
CN105732634A (zh) 2016-07-06
US20090281079A1 (en) 2009-11-12
AR057991A1 (es) 2008-01-09
ES2459016T3 (es) 2014-05-07
CN101365454A (zh) 2009-02-11
JP2009519905A (ja) 2009-05-21
BRPI0619153B8 (pt) 2021-05-25
US8829185B2 (en) 2014-09-09
CA2631775A1 (en) 2007-06-07
EP2465505A1 (en) 2012-06-20
AU2006320480B2 (en) 2011-11-10
KR20080083651A (ko) 2008-09-18
DOP2006000269A (es) 2007-07-31
CA2631775C (en) 2015-02-03
UY29983A1 (es) 2007-06-29
JP5199882B2 (ja) 2013-05-15
US8133995B2 (en) 2012-03-13
HK1129305A1 (zh) 2009-11-27
WO2007064883A2 (en) 2007-06-07
EP1957077B1 (en) 2014-01-22
IL191864A (en) 2017-03-30
BRPI0619153A8 (pt) 2019-11-12
EP1957077A2 (en) 2008-08-20
TWI388560B (zh) 2013-03-11
ZA200805694B (en) 2009-11-25
US20120165314A1 (en) 2012-06-28
WO2007064883A3 (en) 2007-10-25
EP1957077A4 (en) 2010-01-13
KR101404290B1 (ko) 2014-06-20
AU2006320480A1 (en) 2007-06-07
BRPI0619153B1 (pt) 2020-01-28
TW200738724A (en) 2007-10-16
IL191864A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
PE20121509A1 (es) Compuestos de triazolopiridinas como inhibidores de quinasa mps-1
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
DK1755606T4 (da) Quinazolinonderivater, der er anvendelige som vanilloid-antagonister
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
RU2009141982A (ru) Пиримидиновые производные
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
RS53688B1 (en) 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
MEP8409A (en) Fused heterocyclic compound
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed